IFRX InflaRx: Company Value to Revenue Ratio

InflaRx N.V. (IFRX) is expanding its market presence following the approval of Gohibic for emergency therapy. The EV/Sales history illustrates the business valuation trend, where the metric remains around 0.00. Finances rely on government subsidies and the prospects of vilobelimab, while structural flexibility is ensured by fully outsourcing production and clinical trials to external partners.
IFRX (InflaRx): analytical breakdowns and indicator data

Professional capital evaluates the profile of InflaRx N.V. (IFRX) through the lens of market capitalization and net debt-to-sales, which offsets the impact of credit leverage on asset value. By analyzing the enterprise value-to-revenue trend, the investor determines whether the stock is overbought, a critical factor for a biotech company with a high concentration of R&D, where US drug approvals mitigate binary risks and enhance investment reliability.